Affymetrix Launches Most Comprehensive Array Offering for Microbiology Research
16 November 2004 - 9:00AM
PR Newswire (US)
Affymetrix Launches Most Comprehensive Array Offering for
Microbiology Research 179 New Prokaryotic Designs Provide Rapid,
Cost-Efficient Solution for Microbial Whole-Genome Expression
Studies SANTA CLARA, Calif., Nov. 15 /PRNewswire-FirstCall/ --
Affymetrix, Inc. (NASDAQ:AFFX) today announced the launch of 179
NimbleExpress(TM) prokaryotic array designs, providing researchers
with the most comprehensive catalog offering of microarray
expression products for basic microbiology and infectious disease.
These arrays offer scientists an affordable tool to conduct
whole-genome expression studies on a wide range of pathogenic
organisms, including Bacillus anthracis, Haemophilus influenzae,
and Mycobacterium tuberculosis. Affymetrix microarrays have been
used in many phases of microbial research, from studying costly
agricultural pathogens to studying life-threatening human diseases.
In infectious disease research alone, GeneChip(R) arrays have been
used in nearly 200 scientific publications to understand the
relationships between hosts and pathogens and to discover new
vaccines and treatments that can be used to combat disease. "With
this new line of NimbleExpress arrays, individual researchers can
use industry-standard Affymetrix technology to conduct a broader
range of microbial expression studies more effectively and
cost-efficiently than ever before," said Lianne McLean, Director,
Gene Expression Marketing, Affymetrix. "Instead of spending their
time designing and manufacturing arrays, scientists can begin
experiments immediately, often allowing them to more quickly
understand disease and improve health." These new prokaryotic
designs are part of an expanded NimbleExpress Array Program that
recently launched to provide Affymetrix customers with a flexible,
cost-effective method of designing customized expression arrays (up
to 12,000 transcripts) for smaller scale studies or pilot
experiments. NimbleExpress arrays are manufactured by NimbleGen
Systems Inc. for Affymetrix using a photolithographic Maskless
Array Synthesis (MAS) technology. The two companies have
collaborated on the design of the arrays which feature Affymetrix'
proven strategy of multiple pairs of perfect match and mismatch
oligos per transcript for the best balance of sensitivity and
specificity. NimbleExpress Arrays are compatible with the latest
generation GeneChip System, which includes new instruments,
reagents, and high-performance analysis algorithms. All
NimbleExpress microarrays are individually produced and quality
tested, to ensure that they meet Affymetrix' high standards for
quality and reproducibility. For more information about
NimbleExpress arrays, please visit http://www.affymetrix.com/.
About Affymetrix: Affymetrix is a pioneer in creating breakthrough
tools that are driving the genomic revolution. By applying the
principles of semiconductor technology to the life sciences,
Affymetrix develops and commercializes systems that enable
scientists to improve the quality of life. The Company's customers
include pharmaceutical, biotechnology, agrichemical, diagnostics
and consumer products companies as well as academic, government and
other non-profit research institutes. Affymetrix offers an
expanding portfolio of integrated products and services, including
its integrated GeneChip brand platform, to address growing markets
focused on understanding the relationship between genes and human
health. Additional information on Affymetrix can be found at
http://www.affymetrix.com/. All statements in this press release
that are not historical are "forward-looking statements" within the
meaning of Section 21E of the Securities Exchange Act as amended,
including statements regarding Affymetrix' "expectations,"
"beliefs," "hopes," "intentions," "strategies" or the like. Such
statements are subject to risks and uncertainties that could cause
actual results to differ materially for Affymetrix from those
projected, including, but not limited to risks of the Company's
ability to achieve and sustain higher levels of revenue, higher
gross margins, reduced operating expenses, uncertainties relating
to technological approaches, manufacturing, product development,
market acceptance (including uncertainties relating to product
development, use and market acceptance of the GeneChip(R)
NimbleExpress(TM) Arrays), personnel retention, uncertainties
related to cost and pricing of Affymetrix products, dependence on
collaborative partners, uncertainties relating to sole source
suppliers, uncertainties relating to FDA and other regulatory
approvals, competition, risks relating to intellectual property of
others and the uncertainties of patent protection and litigation.
These and other risk factors are discussed in Affymetrix' Form 10-K
for the year ended December 31, 2003 and other SEC reports,
including its Quarterly Reports on Form 10-Q for subsequent
quarterly periods. Affymetrix expressly disclaims any obligation or
undertaking to release publicly any updates or revisions to any
forward-looking statements contained herein to reflect any change
in Affymetrix' expectations with regard thereto or any change in
events, conditions, or circumstances on which any such statements
are based. NOTE: Affymetrix, the Affymetrix logo, and GeneChip are
registered trademarks owned or used by Affymetrix, Inc. DATASOURCE:
Affymetrix, Inc. CONTACT: media, Wes Conard, Associate Director,
Public Relations, +1-408-731-5791, or investors, Doug Farrell, Vice
President, Investor Relations, +1-408-731-5285, both of Affymetrix,
Inc. Web site: http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024